The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-16 and is reviewed periodically as new material appears.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
=== Ocular hypertension === Ocular hypertension (increased pressure within the eye) is an important risk factor for glaucoma, but only about 10–70% of people, depending on ethnic group, with primary open-angle glaucoma actually have elevated ocular pressure. Ocular hypertension—an intraocular pressure above the traditional threshold of 21 mmHg (28 hPa) or even above 24 mmHg (32 hPa)—is not necessarily a pathological condition, but it increases the risk of developing glaucoma. A study with 1636 persons aged 40–80 who had an intraocular pressure above 24 mmHg in at least one eye, but no indications of eye damages, showed that after five years, 9.5% of the untreated participants and 4.4% of the treated participants had developed glaucomatous symptoms, meaning that only about one in 10 untreated people with elevated intraocular pressure will develop glaucomatous symptoms over that period. Given these results, the clinical decision to treat everyone with elevated intraocular pressure with glaucoma therapy as a preventative measure is a matter of debate. As of 2018, most ophthalmologists favored treatment of those with additional risk factors. For eye pressures, a value of 28 hPa (21 mmHg) above atmospheric pressure 1,010 hPa (760 mmHg) is often used, with higher pressures leading to a greater risk. However, some may have high eye pressure for years and never develop damage. Conversely, optic nerve damage may occur with normal pressure, known as normal-tension glaucoma.
It performs antimicrobial functions in microorganisms like algae, fungi, bacteria, and gram-positive bacteria of different yeast species. Chitosan composite for tissue engineering: Chitosan powder blended with alginate is used to form functional wound dressings. These dressings create a moist, biocompatible environment which aids in the healing process. This wound dressing is also biodegradable and has porous structures that allows cells to grow into the dressing. Furthermore, thiolated chitosans (see thiomers) are used for tissue engineering and wound healing, as these biopolymers are able to crosslink via disulfide bonds forming stable three-dimensional networks.
=== Environmental factors === A significant number of environmental factors have been implicated in the development and progression of various autoimmune diseases, either directly or as catalysts. Current research suggests that up to seventy percent of autoimmune diseases could be attributed to environmental influences, which encompass an array of elements such as chemicals, infectious agents, dietary habits, and gut dysbiosis. However, a unifying theory that definitively explains the onset of autoimmune diseases remains elusive, emphasizing the complexity and multifaceted nature of these conditions. Various environmental triggers are identified, some of which include:
PmF3 + 3 Li → Pm + 3 LiF The promethium sample produced was used to measure a few of the metal's properties, such as its melting point. In 1963, ion-exchange methods were used at ORNL to prepare about ten grams of promethium from nuclear reactor fuel processing wastes. Promethium can be either recovered from the byproducts of uranium fission or produced by bombarding 146Nd with neutrons, turning it into 147Nd, which decays into 147Pm through beta decay with a half-life of 11 days.
Sources: en.wikipedia.org
==== Proboscidean research ==== A study on the morphology of the astragalus and calcaneus in extant and extinct proboscideans, providing evidence of morphological changes of ankles bones related to increase of the body mass and evolution of the columnar posture of members of the group, is published by Tetaert et al. (2026). A study on humeri of extant and extinct proboscideans, providing evidence of different impact of compressive loading on humeri representing slender and robust morphotypes, is published by Wagner, Chatar & Hennekam (2026). Semprebon, Sanders & Uttecht (2026) reconstruct diets and habitats of Moeritherium and Phiomia on the basis of their tooth wear, interpreting the former taxon as feeding on soft vegetation and likely frequenting aquatic habitats, and interpreting the latter taxon as likely living in a terrestrial forest or woodland environment. Alquézar-Blesa et al. (2026) study the feeding behaviors of Miocene Gomphotherium and Prodeinotherium from Artesilla and Tarazona (Spain), reporting evidence from the study of tooth wear indicative of a greater degree of dietary flexibility than indicated by tooth morphology, including evidence of grass consumption. Bader, Gasparik & Segesdi (2026) compare the microanatomy of femur of Deinotherium giganteum and mammoths, reporting evidence of differences that might be linked to distinct weight-bearing adaptations. Description of new fossil material of Mammut shansiense from the Yushe Basin (China) and a study on the phylogenetic affinities of the species is published by Zhang et al.
The calculus for peak oil has changed with the introduction of unconventional production methods. In particular, the combination of horizontal drilling and hydraulic fracturing has resulted in a significant increase in production from previously uneconomic plays. Certain rock strata contain hydrocarbons but have low permeability and are not thick from a vertical perspective. Conventional vertical wells would be unable to economically retrieve these hydrocarbons. Horizontal drilling, extending horizontally through the strata, permits the well to access a much greater volume of the strata. Hydraulic fracturing creates greater permeability and increases hydrocarbon flow to the wellbore.
=== DNA damage and cellular stress === CK1δ can be also activated by genotoxic stress and DNA damage in a p53-dependent manner, and phosphorylate key regulatory proteins in response to these processes. CK1δ phosphorylates human p53 on Ser-6, Ser-9, and Ser-20. Moreover, CK1δ phosphorylates p53 on Thr-18, once p53 is already phospho-primed, permitting a lower p53-Mdm2 binding and higher p53 activity. Under normal conditions, CK1δ can phosphorylate Mdm2 on Ser-240, Ser-242, Ser-246, and Ser-383, permitting higher p53-Mdm2 stability and further p53 degradation. On the contrary, after DNA damage, ATM phosphorylates CK1δ, which can subsequently phosphorylate Mdm2 inducing its proteasomal degradation. Under hypoxia, CK1δ is involved in reducing cell proliferation by interfering with HIF-1α/ARNT complex formation. Additionally, the activity of topoisomerase II α (TOPOII-α), one of the main regulators of DNA replication, results increased after its CK1δ-mediated phosphorylation on Ser-1106. Under stress conditions, CK1δ can interfere with DNA replication. In fact, CK1δ phosphorylates a main regulator of DNA methylation, the ubiquitin-like containing PHD and RING finger domains 1 protein (UHRF1), on Ser-108, increasing its proteasomal degradation.
== Regulation around the world == On 6 July 2012, the international reference standard Codex Alimentarius Commission narrowly approved the adoption of a maximum residue limit (MRL) of 10 parts per billion (ppb) for muscle cuts of beef and pork. Setting any limit was a controversial move. Countries with major meat export markets had been lobbying for the establishment of such a standard for several years to use it as leverage to erode individual national-level bans in World Trade Organization disputes. Consumers International, a world federation of consumer groups that represents 220 consumer organizations in 115 countries, strongly opposed the move. A 2020 petition to the Food and Drug Administration to reconsider the approval of ractopamine stated that 168 other nations had banned or restricted its use. In 2025 and in response to an unreasonable delay lawsuit, the FDA responded acknowledging the number had increased from 160 in 2012, and questioned the relevance of the figure.
=== 1 June === Three people, including a mother and her child, were killed in a Russian air attack on Kyiv in the early hours of the day. The victims were from the Desnianskyi District. Reports said that the casualties were trying to access a locked bomb shelter when the attack occurred. Four people were detained in connection to the incident, namely a security guard, the director of a medical facility, his deputy and the first deputy of the district administration. A subsequent audit of Kyiv's bomb shelters found that nearly half of them were unfit for use or closed. Damage was also reported in the Dniprovskyi District. Ten Iskander missiles were intercepted according to the Ukrainian military. In Russia's Belgorod Oblast, eight people were reported to have been injured by Ukrainian shelling in Shebekino. The regional governor, Vyacheslav Gladkov, claimed that Ukrainian forces used Grad rockets. Two others were injured in a drone attack in Belgorod city. The Russian defence ministry claimed it had repulsed three Ukrainian attacks on Belgorod, killed more than 50 Ukrainian soldiers and destroyed four armored vehicles. It said the attacks involved up to 70 "militants", five tanks, four armoured vehicles, seven pick-up trucks and a Kamaz truck. The Ukrainian Ministry of Infrastructure said the Black Sea Grain Initiative had been halted again because Russia had blocked the registration of ships to all Ukrainian ports.
Sources: en.wikipedia.org
Aquaphor was developed in 1925 in the United States laboratories of Beiersdorf Inc. It was trademarked that year by Herman A. Metz, the company's president. In 1929, Beiersdorf sold the Aquaphor trademarks to Duke Laboratories to facilitate manufacturing in the country. In 1936, Aquaphor's first product offering was sold to doctors, pharmacists and hospitals in 5 lb. containers. Production was discontinued during World War II but resumed by Duke Laboratories in 1960. At that time, 1 lb cans and 2 oz tubes were sold to medical professionals. Beiersdorf repurchased the trademarks from Duke Laboratories in 1973. In 1982, the product was sold directly to consumers for the first time. The formulation was expanded in 1991 with the launch of "Advanced Therapy Healing Ointment", an addition to the original ointment. Beiersdorf further expanded the brand in the early 2000s, introducing baby products in 2003 and a lip repair line in 2011. In 2012, the brand launched globally in 25 other countries. In 2013, Aquaphor achieved the Good Housekeeping Seal.
== Mechanisms == The mechanism by which dedifferentiation occurs has not been completely illuminated. The pathways discussed below are found to be closely related to dedifferentiation and regeneration in some species. Because not one pathway has been elucidated as necessary for all dedifferentiation and regeneration, the mechanism may function differently in different species.
Neurolathyrism is caused by the consumption of large quantities of Lathyrus grain, specifically the grains in the genus that contain the glutamate analogue neurotoxin ODAP (also known as β-N-oxalyl-amino-L-alanine, or BOAA). Lathyrus sativus (also known as grass pea, chickling pea, kesari dal, or almorta) and to a lesser degree with Lathyrus cicera, Lathyrus ochrus and Lathyrus clymenum
== Toxicity == Since 2016, G. biloba extract is classified as a possible human carcinogen (group 2B) by the International Agency for Research on Cancer. When eaten in large quantities or over a long period, the seeds may cause poisoning by ginkgotoxin (4'-O-methylpyridoxine, MPN), as found in a few case reports. A heat-stable compound not destroyed by cooking, MPN may cause convulsions, which were alleviated by treatment with pyridoxine phosphate (vitamin B6), according to limited studies. Some people are sensitive to the chemicals in the sarcotesta, the outer fleshy coating. These people should handle the seeds with care, wearing disposable gloves, when preparing them for consumption. The symptoms are allergic contact dermatitis, or blisters similar to that caused by contact with poison ivy. Side effects of using ginkgo supplements may include increased risk of bleeding, gastrointestinal discomfort, nausea, vomiting, diarrhea, headaches, dizziness, heart palpitations, and restlessness. Although use of standardized Ginkgo biloba leaf extracts in moderate amounts appears to be safe, excessive use may have undesirable effects, especially in terms of drug interactions. The dosing of anticoagulants, such as warfarin or antiplatelet medication, may be adversely affected by using ginkgo supplements. According to a systematic review, the effects of ginkgo on pregnant women may include increased bleeding time, and there is inadequate information about safety during lactation. Ginkgo pollen may produce allergic reactions. G.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.